Coinbase Founder’s Longevity Startup Triples in Value

The rapid growth of Coinbase founder’s longevity startup NewLimit to a $3.1 billion valuation highlights the increasing investment and innovation in biotech and health tech sectors. Its upcoming clinical trials for alcohol-related liver disease could revolutionize treatments and extend healthy lifespans, impacting both consumers and the broader healthcare industry.

• NewLimit's valuation tripled, signaling strong investor confidence in longevity biotech.
• The startup's focus on RNA therapy represents cutting-edge advancements in personalized medicine.
• Successful clinical trials could lead to significant breakthroughs in treating liver diseases and extending lifespan.